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Clinical PerspectiveWhat Is New?In patients with chronic kidney disease, high‐sensitivity troponin T (TnT) is strongly associated with alterations of left ventricular structure and diastolic dysfunction, regardless of estimated glomerular filtration rate strata.Baseline levels of high‐sensitivity TnT are predictive of new left ventricular hypertrophy on follow‐up.What Are the Clinical Implications?This research suggests that a high‐sensitivity TnT assay could be a useful targeted strategy for risk stratification of patients who may need further cardiac evaluation, regardless of renal function.Further studies are needed to confirm the ideal cutoff values for high‐sensitivity TnT in chronic kidney disease.

Introduction {#jah34438-sec-0008}
============

Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). It is important to identify risk factors for prevention of cardiovascular disease in patients with CKD to facilitate treatment in the asymptomatic phase. Although pathologic changes in cardiac structure including left ventricular hypertrophy (LVH) may affect cardiovascular mortality,[1](#jah34438-bib-0001){ref-type="ref"}, [2](#jah34438-bib-0002){ref-type="ref"} they do not produce definite cardiac symptoms. For these reasons, physicians and researchers have invested considerable effort into identifying biomarkers related to subclinical changes in cardiac structure.

The conventional cardiac troponin T (TnT) assay has become a widely used biomarker for diagnosing acute coronary syndrome.[3](#jah34438-bib-0003){ref-type="ref"} Troponin assays have continued to evolve, and a high‐sensitivity TnT (hs‐TnT) assay with detection limits 10 to 100 times lower than conventional assays is now available. Importantly, hs‐TnT can be detected in asymptomatic patients with no history of cardiovascular disease.

Chronically elevated levels of hs‐TnT were recently shown to be associated with chronic subclinical myocardial damage in the general population, including left ventricular (LV) structure abnormalities.[4](#jah34438-bib-0004){ref-type="ref"}, [5](#jah34438-bib-0005){ref-type="ref"}, [6](#jah34438-bib-0006){ref-type="ref"} However, patients with CKD have persistently elevated TnT levels compared with those with normal renal function.[7](#jah34438-bib-0007){ref-type="ref"} In addition, chronic structural and functional abnormalities of the heart are common among CKD patients.[8](#jah34438-bib-0008){ref-type="ref"} Because hs‐TnT is easier to obtain in an outpatient setting and is relatively low in cost compared with a traditional echocardiogram, there is an important and clinically relevant need to define cardiac structural and functional correlates of hs‐TnT levels.[9](#jah34438-bib-0009){ref-type="ref"} The ability to interpret elevated troponin levels in CKD patients is critical, as their elevation may predict clinical and subclinical cardiac injury in patients with or without CKD.

To better understand the implication of elevated hs‐TnT level in CKD patients across a broad range of estimated glomerular filtration rates (eGFRs), we investigated the association between hs‐TnT and LV structure and function based on 2 different eGFR strata in the KNOW‐CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease), which comprises patients with both mild and severe renal dysfunction.

Methods {#jah34438-sec-0009}
=======

This study was performed using the database extracted from KNOW‐CKD, a Korean multicenter prospective cohort study that enrolled patients with non--dialysis‐dependent CKD (stages 1--5) from April 2011 to February 2016. The detailed design and methods for the KNOW‐CKD cohort have been published previously.[10](#jah34438-bib-0010){ref-type="ref"}, [11](#jah34438-bib-0011){ref-type="ref"} The study protocol was approved by the institutional review board at each participating clinical center. The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol summary is registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) under accession number NCT01630486. Written informed consent was obtained from all participants at the time of enrollment. Because of ethical issues and data protection regulations, data that support the findings of the present study cannot be made publicly available.

Briefly, a total of 2238 patients were enrolled in the KNOW‐CKD study. We excluded participants who, at enrollment, (1) did not have an hs‐TnT measurement at our central laboratory, (2) did not have an LV mass index measurement, or (3) had been diagnosed with heart failure. Finally, a total of 2017 patients were included in our cross‐sectional analysis (Figure [1](#jah34438-fig-0001){ref-type="fig"}). Patients who completed follow‐up transthoracic echocardiography after 4 years were included in an analysis of association between baseline hs‐TnT and changes in development of cardiac structure and function (n=864, 42.8% of total participants).

![Study flow. hs‐TnT indicates high‐sensitivity cardiac troponin T (TnT); KNOW‐CKD, Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease; LVMI, left ventricular mass index.](JAH3-8-e013357-g001){#jah34438-fig-0001}

All covariates analyzed in this study were collected at the time of enrollment. The primary predictor for echocardiographic parameters was the hs‐TnT level, which was measured using a highly sensitive electrochemiluminescence immunoassay on an Elecsys 2010, which has an analytical measurement range of 3 to 10 000 pg/mL. We investigated additional parameters including age; sex; body mass index; comorbidities including hypertension, diabetes mellitus, and coronary artery disease; hemoglobin; lipid profile; high‐sensitivity CRP (C‐reactive protein); and eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation with creatinine.[12](#jah34438-bib-0012){ref-type="ref"} Smoking status was categorized as current, ex‐, or never smoker.

The primary outcome was LVH and systolic and diastolic dysfunction. Two‐dimensional echocardiography was conducted at enrollment and during the fourth year of follow‐up. LV mass was calculated using the formula 0.8×{1.04 \[(LVIDd+PWTd+SWTd)^3^−(LVIDd)^3^\]}+0.6 g, where LVIDd refers to LV end‐diastolic internal dimension and PWTd and SWTd are posterior wall thickness at end diastole and septal wall thickness at end diastole, respectively.[13](#jah34438-bib-0013){ref-type="ref"} LV mass was indexed to height (m^2.7^) because LV mass indexed to body surface area is problematic in that weight is affected by volume overload in CKD.[13](#jah34438-bib-0013){ref-type="ref"}, [14](#jah34438-bib-0014){ref-type="ref"}, [15](#jah34438-bib-0015){ref-type="ref"} LVH was defined as an LV mass/height ≥47 g/m^2.7^ in women and ≥50 g/m^2.7^ in men. Relative wall thickness (RWT) was calculated as twice the posterior wall thickness/LV internal linear dimension in diastole. RWT values \>0.42 were considered to be increased.[13](#jah34438-bib-0013){ref-type="ref"} LV mass and RWT were used to classify LV geometry: normal (no LVH and RWT ≤0.42), concentric remodeling (no LVH and RWT \>0.42), eccentric hypertrophy (LVH and RWT ≤0.42), and concentric hypertrophy (LVH and RWT \>0.42). LV systolic dysfunction was defined as an ejection fraction \<50%.[16](#jah34438-bib-0016){ref-type="ref"} Diastolic dysfunction was defined as E/e′ measured at the medial annulus \>15.[17](#jah34438-bib-0017){ref-type="ref"}

Continuous variables are presented as mean±SD. Categorical variables are presented as proportion and frequency. We used 1‐way ANOVA for comparison of continuous variables and the χ^2^ test for categorical variables.

Patients were stratified into 4 groups according to hs‐TnT quartiles. We utilized multivariable logistic regression analysis to evaluate the independent association between hs‐TnT and outcomes of this study. A univariate analysis for each variable was conducted primarily, and the results were used to select the covariates included in the multivariate analysis based on *P*\<0.05. Although some variables did not show statistical significance, variables of clinical importance were included based on the judgment of the researchers.

We stratified participants into 2 subgroups based on eGFR ≥60 or \<60 mL/min per 1.73 m^2^ to evaluate the modifying effect of renal impairment on hs‐TnT. The eGFR strata did not show an interaction with the hs‐TnT level. *P* values for interactions between eGFR strata and hs‐TnT were 0.07, 0.55, and 0.41 for LVH, systolic dysfunction, and diastolic dysfunction, respectively. We carried out additional analyses to investigate whether hs‐TnT can be used as a screening test to detect structural and functional abnormalities. Receiver operating characteristic (ROC) curve analysis was performed for determination of area under the curve. Optimal cutoff concentrations for hs‐TnT were defined as points of the ROC curves by the Youden method.[18](#jah34438-bib-0018){ref-type="ref"} In addition, we conducted multivariate ROC analysis adjusted to covariables selected in the previous logistic regression, and the areas under the curve were compared according to renal function. Pairwise comparisons among the areas under the curve were made using the Delong method.[19](#jah34438-bib-0019){ref-type="ref"}

A 2‐tailed *P*\<0.05 was used as the cutoff for statistical significance. All statistical analyses were performed using R (v3.5.2; R Foundation for Statistical Computing) and SAS (v9.4; SAS Institute).

Results {#jah34438-sec-0010}
=======

The overall distribution of hs‐TnT was skewed to the right, and we observed an inverse relationship between hs‐TnT and eGFR (Figure [S1](#jah34438-sup-0001){ref-type="supplementary-material"}). The mean participant age was 53.5±12.2 years, and 1229 (60.9%) patients were men (Table [1](#jah34438-tbl-0001){ref-type="table"}). The median hs‐TnT level was 10.0 pg/mL (interquartile range: 6.0--16.0 pg/mL), and the mean eGFR was 53.6±30.9 mL/min per 1.73 m^2^. Participants with higher hs‐TnT levels were older and more likely to be male and tended to have lower eGFRs and higher systolic blood pressures. In addition, higher hs‐TnT concentrations indicated higher percentages of patients diagnosed with diabetic or hypertensive nephropathy.

###### 

Baseline Characteristics of Participants According to hs‐TnT Level

                                                Total (N=2017)         TnT Category (pg/mL)   *P* Value             *P* for Trend                                            
  --------------------------------------------- ---------------------- ---------------------- --------------------- ---------------------- ----------------------- --------- ---------
  Age, y                                        53.5±12.2              46.0±10.6              51.6±11.4             58.5±10.9              59.1±10.9               \<0.001   \<0.001
  Sex                                                                                                                                                              \<0.001   \<0.001
  Female                                        788 (39.1)             288 (55.7)             223 (38.5)            155 (35.6)             122 (25.2)                        
  Male                                          1229 (60.9)            229 (44.3)             356 (61.5)            281 (64.4)             363 (74.8)                        
  BMI, kg/m^2^                                  24.6±3.4               24.0±3.5               24.6±3.2              24.7±3.3               25.1±3.4                \<0.001   \<0.001
  Blood pressure                                                                                                                                                             
  SBP, mm Hg                                    127.9±16.2             125.0±14.1             126.3±14.8            127.7±15.6             133.2±18.9              \<0.001   \<0.001
  DBP, mm Hg                                    77.1±11.1              78.3±10.5              77.5±10.3             75.7±10.7              76.5±12.7               0.002     \<0.001
  MAP, mm Hg                                    94.0±11.6              93.8±10.9              93.8±10.9             93.1±11.0              95.4±13.6               0.02      0.20
  Current smoker                                325 (16.1)             79 (15.3)              97 (16.8)             76 (17.4)              73 (15.1)               \<0.001   
  DM                                            673 (33.4)             60 (11.6)              112 (19.3)            172 (39.4)             329 (67.8)              \<0.001   \<0.001
  Hypertension                                  1937 (96.0)            466 (90.1)             563 (97.2)            432 (99.1)             476 (98.1)              \<0.001   \<0.001
  CAD                                           102 (5.1)              4 (0.8)                18 (3.1)              28 (6.4)               52 (10.7)               \<0.001   \<0.001
  Cause of CKD                                                                                                                                                     \<0.001   0.10
  Diabetic nephropathy                          466 (23.1)             21 (4.1)               52 (9.0)              122 (28.0)             271 (55.9)                        
  Glomerulonephritis                            720 (35.7)             232 (44.9)             283 (48.9)            128 (29.4)             77 (15.9)                         
  Hypertensive nephropathy                      368 (18.2)             56 (10.8)              100 (17.3)            118 (27.1)             94 (19.4)                         
  ADPKD                                         344 (17.1)             181 (35.0)             115 (19.9)            35 (8.0)               13 (2.7)                          
  Unknown                                       119 (5.9)              27 (5.2)               29 (5.0)              33 (7.6)               30 (6.2)                          
  eGFR, mL/min/1.73 m^2^                        53.6±30.9              80.9±28.9              58.6±26.2             40.9±21.7              29.8±17.3               \<0.001   \<0.001
  CKD stage                                                                                                                                                        \<0.001   \<0.001
  Stage 1                                       335 (16.6)             217 (42.0)             91 (15.7)             21 (4.8)               6 (1.2)                           
  Stage 2                                       385 (19.1)             162 (31.3)             152 (26.3)            46 (10.6)              25 (5.2)                          
  Stage 3a                                      328 (16.3)             72 (13.9)              131 (22.6)            85 (19.5)              40 (8.2)                          
  Stage 3b                                      428 (21.2)             50 (9.7)               132 (22.8)            131 (30.0)             115 (23.7)                        
  Stage 4                                       417 (20.7)             14 (2.7)               64 (11.1)             120 (27.5)             219 (45.2)                        
  Stage 5                                       124 (6.1)              2 (0.4)                9 (1.6)               33 (7.6)               80 (16.5)                         
  Laboratory findings                                                                                                                                                        
  CRP, mg/dL                                    2.0±5.2                1.5±4.3                1.9±4.6               2.2±5.5                2.5±6.5                 0.01      \<0.001
  HDL, mg/dL                                    49.3±15.5              54.2±15.9              50.7±14.7             46.3±13.4              45.0±15.9               \<0.001   \<0.001
  Triglyceride, mg/dL                           157.4±97.9             144.6±89.9             155.4±98.4            163.2±93.2             167.7±107.5             0.001     
  Hemoglobin, g/dL                              12.9±2.0               13.6±1.7               13.4±1.9              12.5±2.0               11.7±1.9                \<0.001   \<0.001
  Urine protein/creatinine ratio (g/g, IQR)     0.5 (0.1--1.5)         0.3 (0.07--0.7)        0.3 (0.1--0.9)        0.5 (0.2--1.5)         1.4 (0.5--3.4)          \<0.001   \<0.001
  Urine albumin/creatinine ratio (mg/mg, IQR)   347.7 (76.8--1052.1)   167.5 (27.9--530.0)    242.8 (59.1--665.7)   366.4 (83.3--1063.2)   997.0 (350.8--2378.9)   \<0.001   \<0.001
  Data from echocardiography                                                                                                                                                 
  LVMI, g/m^2.7^                                41.9±11.5              36.6±9.0               39.7±9.2              43.8±10.7              48.3±13.5               \<0.001   \<0.001
  LVH                                           483 (23.9)             56 (10.8)              92 (15.9)             129 (29.6)             206 (42.5)              \<0.001   \<0.001
  LV geometry                                                                                                                                                      \<0.001   \<0.001
  Normal                                        1237 (61.3)            392 (75.8)             400 (69.1)            246 (56.4)             199 (41.0)                        
  Concentric LVH                                245 (12.1)             38 (7.4)               58 (10.0)             55 (12.6)              94 (19.4)                         
  Concentric remodeling                         294 (14.6)             57 (11.0)              87 (15.0)             70 (16.1)              80 (16.5)                         
  Eccentric LVH                                 236 (11.7)             29 (5.6)               33 (5.7)              64 (14.7)              110 (22.7)                        
  E/E′                                          9.9±3.7                8.3±2.4                9.2±3.0               10.4±3.8               11.9±4.4                \<0.001   \<0.001
  Ejection fraction, %                          64.2±5.9               63.8±5.6               64.7±5.6              64.1±5.8               64.2±6.7                0.08      0.04
  Systolic dysfunction                          21 (1.0)               2 (0.4)                4 (0.7)               4 (0.9)                11 (2.3)                \<0.001   \<0.001
  Diastolic dysfunction                         167 (8.3)              8 (1.5)                26 (4.5)              47 (10.8)              86 (17.7)               \<0.001   \<0.001

Data are shown as mean±SD or n (%). ADPKD indicates autosomal dominant polycystic kidney disease; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C‐reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; hs‐TnT, high‐sensitivity troponin T; IQR, interquartile range; LV, left ventricular; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; MAP, mean arterial pressure; SBP, systolic blood pressure.

Overall, 483 patients (23.9%) had LVH on echocardiography. LV mass index increased gradually across the hs‐TnT quartile groups. The proportion of concentric LVH, concentric remodeling, and eccentric LVH all gradually increased across the quartiles of cardiac TnT concentration (Figure [2](#jah34438-fig-0002){ref-type="fig"}). There were 21 patients (1.0%) with systolic dysfunction and 167 patients (8.3%) with diastolic dysfunction. The proportions of both LV dysfunctions were higher in patients with higher hs‐TnT levels than in those with lower levels.

![Elevated hs‐TnT levels are associated with LVH in patients with chronic kidney disease. With increasing quartiles of hs‐TnT, the prevalence of concentric and eccentric LVH and concentric remodeling increases. hs‐TnT indicates high‐sensitivity cardiac troponin T; LVH, left ventricular hypertrophy;](JAH3-8-e013357-g002){#jah34438-fig-0002}

In the univariate analysis, LVH and systolic and diastolic dysfunction were related to increment of hs‐TnT (Table [S1](#jah34438-sup-0001){ref-type="supplementary-material"}). Table [2](#jah34438-tbl-0002){ref-type="table"} summarizes the independent association between hs‐TnT and LVH or diastolic dysfunction with multivariable analysis. At baseline, the 2 highest quartiles of hs‐TnT were found to have an odds ratio \>2 for LVH in the fully adjusted model (*P* for trend \<0.001; Figure [3](#jah34438-fig-0003){ref-type="fig"}). The eGFR strata did not show a statistically significant interaction for the hs‐TnT level in both LVH and diastolic dysfunction (*P*=0.07 and *P*=0.41, respectively, for interactions). The highest quartiles of hs‐TnT were significantly associated with LVH in both eGFR strata, suggesting the results were independent of renal function in multivariable analysis. No significant association between hs‐TnT and systolic dysfunction was identified in multivariable analysis. Higher hs‐TnT concentrations were independently associated with diastolic dysfunction in our fully adjusted model (*P*\<0.001 for trend). In a stratified analysis according to eGFR, diastolic dysfunction continued to show a significant relationship with the highest hs‐TnT range for both eGFR strata.

###### 

Association Between hs‐TnT and LV Structure and Functional Abnormalities According to eGFR

                               hs‐TnT (pg/mL)        Odds of LVH[a](#jah34438-note-0004){ref-type="fn"}   *P* Value            Odds of Systolic Dysfunction[b](#jah34438-note-0005){ref-type="fn"}   *P* Value             Odds of Diastolic Dysfunction[c](#jah34438-note-0006){ref-type="fn"}   *P* Value
  ---------------------------- --------------------- ---------------------------------------------------- -------------------- --------------------------------------------------------------------- --------------------- ---------------------------------------------------------------------- -----------
  Total patients               ≤6.0                  1.00 (reference)                                                          1.00 (reference)                                                                            1.00 (reference)                                                       
  \>6.0--10.0                  1.17 (0.78--1.78)     0.46                                                 1.06 (0.20--7.87)    0.95                                                                  2.60 (1.11--6.84)     0.03                                                                   
  \>10.0--16.0                 2.02 (1.29--3.19)     0.002                                                1.23 (0.20--10.07)   0.83                                                                  4.77 (2.012--12.80)   \<0.001                                                                
  \>16.0                       3.17 (1.94--5.25)     \<0.001                                              2.20 (0.41--17.50)   0.39                                                                  7.71 (3.10--21.49)    \<0.001                                                                
  eGFR ≥60 mL/min/1.73 m^2^    ≤6.0                  1.00 (reference)                                                          1.00 (reference)                                                                            1.00 (reference)                                                       
  \>6.0--10.0                  1.35 (0.73--2.49)     0.33                                                 1.08 (0.08--14.00)   0.95                                                                  1.64 (0.44--6.8548)   0.46                                                                   
  \>10.0--16.0                 1.86 (0.77--4.35)     0.15                                                 3.91 (0.27--55.70)   0.29                                                                  1.72 (0.358--8.59)    0.49                                                                   
  \>16.0                       14.75 (4.72--48.37)   \<0.001                                              6.02 (0.38--94.00)   0.18                                                                  12.41 (2.42--70.27)   0.003                                                                  
  eGFR \<60 mL/min/1.73 m^2^   ≤6.0                  1.00 (reference)                                                          1.00 (reference)                                                                            1.00 (reference)                                                       
  \>6.0--10.0                  0.87 (0.488--1.60)    0.65                                                 1.05 (0.13--21.79)   0.96                                                                  1.97 (0.62--8.73)     0.29                                                                   
  \>10.0--16.0                 1.54 (0.865--2.83)    0.15                                                 0.86 (0.09--18.87)   0.91                                                                  3.96 (1.31--17.23)    0.03                                                                   
  \>16.0                       2.17 (1.174--4.12)    0.01                                                 1.63 (0.22--33.79)   0.68                                                                  6.24 (2.00--27.67)    0.005                                                                  

eGFR indicates estimated glomerular filtration rate; hs‐TnT, high‐sensitivity troponin T; LV, left ventricular; LVH, left ventricular hypertrophy.

LVH: adjusted for age, sex, mean arterial pressure, diabetes mellitus, hypertension, coronary artery disease, chronic kidney disease stage, body mass index, high‐density lipoprotein, triglyceride, and hemoglobin.

Systolic dysfunction: adjusted for age, sex, coronary artery disease, chronic kidney disease stage.

Diastolic dysfunction: adjusted for age, sex, diabetes mellitus, hypertension, chronic kidney disease stage, body mass index, high‐density lipoprotein, triglyceride, C‐reactive protein, and smoking history.

![Association between hs‐TnT and left ventricular structure and function at baseline echocardiography. **A**, Left ventricular hypertrophy: adjusted for age, sex, mean arterial pressure, DM, hypertension, coronary artery disease, CKD stage, mean arterial pressure, BMI, HDL (high‐density lipoprotein), triglyceride, hemoglobin. **B**, Systolic dysfunction: adjusted for age, sex, coronary artery disease, CKD stage. **C**, Diastolic dysfunction: adjusted for age, sex, DM, hypertension, CKD stage, BMI,HDL, triglyceride, CRP (C‐reactive protein), smoking history. BMI indicates body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; hs‐TnT, high‐sensitivity troponin T. \* indicates *P*\<0.05.](JAH3-8-e013357-g003){#jah34438-fig-0003}

We next evaluated whether hs‐TnT as a continuous value can be used as a screening test for LVH and LV function in a CKD population (Table [3](#jah34438-tbl-0003){ref-type="table"}). Levels of hs‐TnT exhibited fair significance for detection of each outcome. By ROC analysis, the optimized hs‐TnT cutoff value for LVH was 9 pg/mL for patients with an eGFR ≥60 mL/min per 1.73 m^2^ and 15 pg/mL for those with an eGFR \<60 mL/min per 1.73 m^2^, respectively. With respect to diastolic dysfunction, the optimized hs‐TnT cutoff values were 9 and 14 pg/mL for patients with eGFRs ≥60 and \<60 mL/min per 1.73 m^2^, respectively. When comparing the multivariable ROC curves with other covariates for the 2 eGFR strata, the differences between the 2 curves were statistically significant for both LVH and diastolic dysfunction (Figure [S2](#jah34438-sup-0001){ref-type="supplementary-material"}).

###### 

hs‐TnT as a Single Diagnostic Test for LVH and Diastolic Dysfunction

                               AUC (95% CI)         Optimal Cutoff (pg/mL)   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)   Positive LR   Negative LR
  ---------------------------- -------------------- ------------------------ ----------------- ----------------- --------- --------- ------------- -------------
  LVH                                                                                                                                              
  Total participants           0.69 (0.66--0.72)    10                       69.4              61.8              13.5      83.6      1.8           0.5
  eGFR ≥60 mL/min/1.73 m^2^    0.63 (0.585--0.68)   9                        38.7              81.9              11.7      74.5      2.3           0.8
  eGFR \<60 mL/min/1.73 m^2^   0.64 (0.61--0.68)    15                       56.2              63.9              24.0      57.2      1.4           0.5
  Systolic dysfunction                                                                                                                             
  Total participants           0.69 (0.58--0.80)    16                       52.4              76.3              0.7       97.7      2.2           0.4
  eGFR ≥60 mL/min/1.73 m^2^    0.78 (0.56--1.00)    8                        75.0              76.1              0.2       98.3      3.1           0.3
  eGFR \<60 mL/min/1.73 m^2^   0.64 (0.49--0.79)    31                       41.2              88.5              0.9       95.5      3.6           0.7
  Diastolic dysfunction                                                                                                                            
  Total participants           0.74 (0.71--0.78)    12                       79.5              57.3              3.5       83.6      2.2           0.4
  eGFR ≥60 mL/min/1.73 m^2^    0.71 (0.63--0.79)    9                        54.3              80.2              2.4       90.3      2.2           0.4
  eGFR \<60 mL/min/1.73 m^2^   0.70 (0.65--0.74)    14                       64.2              60.3              4.9       80.6      1.8           0.5

AUC indicates area under the curve; eGFR, estimated glomerular filtration rate; hs‐TnT, high‐sensitivity cardiac troponin T; LR, likelihood ratio; LVH, left ventricular hypertrophy; NPV, negative predictive value; PPV, positive predictive value.

Among all 2017 enrolled patients, 864 patients underwent follow‐up echocardiography after 4 years of enrollment. Excluding patients who were previously diagnosed with LVH at baseline echocardiography, 86 (12.3%) of 698 patients developed new LVH. Among 828 patients who did not have diastolic dysfunction at baseline, 44 patients (5.3%) developed new diastolic dysfunction at 4 years. Only 7 patients were diagnosed with new systolic dysfunction. The percentage of patients who developed new LVH and diastolic dysfunction increased with elevation of hs‐TnT levels. In terms of LV geometry at 4 years, the results were similar to the baseline in that each proportion of concentric LVH, concentric remodeling, and eccentric LVH increased across the quartiles of cardiac TnT concentration (Figure [S3](#jah34438-sup-0001){ref-type="supplementary-material"}). Finally, multivariable analysis showed that increased hs‐TnT was related to development of LVH (*P*\<0.001 for trend; Figure [4](#jah34438-fig-0004){ref-type="fig"}A) but not to diastolic dysfunction (*P*=0.262 for trend; Figure [4](#jah34438-fig-0004){ref-type="fig"}B).

![The association between hs‐TnT and follow‐up echocardiography. **A**, New LVH: adjusted for age, sex, mean arterial pressure, DM, hypertension, coronary artery disease, CKD stage, BMI, HDL (high‐density lipoprotein), triglyceride, hemoglobin. **B**, New diastolic dysfunction: adjusted to age, sex, DM, hypertension, CKD stage, BMI,HDL, triglyceride, CRP (C‐reactive protein), smoking history. BMI indicates body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; hs‐TnT, high‐sensitivity troponin T; LVH, left ventricular hypertrophy. \* indicates *P*\<0.05.](JAH3-8-e013357-g004){#jah34438-fig-0004}

Discussion {#jah34438-sec-0011}
==========

We investigated the relationship between hs‐TnT and LV structure and function in CKD patients with mild to severe renal dysfunction. Consistent with previous reports,[20](#jah34438-bib-0020){ref-type="ref"}, [21](#jah34438-bib-0021){ref-type="ref"}, [22](#jah34438-bib-0022){ref-type="ref"} increased TnT was independently associated with LVH. To our knowledge, this study is the first regarding the association between diastolic dysfunction and hs‐TnT in predialysis CKD patients. Considering previous reports that hs‐TnT was elevated with lower renal function,[7](#jah34438-bib-0007){ref-type="ref"}, [23](#jah34438-bib-0023){ref-type="ref"}, [24](#jah34438-bib-0024){ref-type="ref"} we conducted further analyses in which we stratified patients into 2 subgroups based on renal function as determined by eGFR. Elevated hs‐TnT was significantly associated with LVH and diastolic dysfunction in both eGFR strata.

As techniques for measuring biomarkers have become more sensitive, it has become easier to detect TnT using a highly sensitive assay. Importantly, growing evidence suggests that elevated hs‐TnT levels in the chronic setting with no cardiac symptoms and without acute coronary syndrome may indicate the presence of chronic subclinical myocardial damage.[4](#jah34438-bib-0004){ref-type="ref"}, [5](#jah34438-bib-0005){ref-type="ref"}, [6](#jah34438-bib-0006){ref-type="ref"} However, a previous retrospective observational study showed that a reduced eGFR is associated with a gradual increase in hs‐TnT at the individual and population levels, meaning there is an inverse relationship between hs‐TnT and eGFR.[23](#jah34438-bib-0023){ref-type="ref"} Reduced renal clearance of TnT in CKD patients has been suggested as an explanation[7](#jah34438-bib-0007){ref-type="ref"}, [25](#jah34438-bib-0025){ref-type="ref"}; however, there is controversy. To date, it has not been clear whether chronic elevation of cardiac troponin levels in CKD patients is related to decreased renal clearance or increased cardiac release. Considering the relationship between renal function and hs‐TnT, it remains unclear whether detection of hs‐TnT in asymptomatic patients is meaningful for identifying chronic myocardial damage. Consequently, one of the greatest advantages of the present study was our assessment of the association between hs‐TnT levels and cardiac structural and functional abnormalities across various stages of CKD, from relatively preserved renal function to severe renal dysfunction.

There seemed to be some differences in hs‐TnT concentrations among various causes of CKD. However, as we reported previously elsewhere,[11](#jah34438-bib-0011){ref-type="ref"} diabetic or hypertensive nephropathy subgroups included more participants with lower eGFR at advanced CKD stages. Therefore, the difference in troponin levels among various CKD causes could be attributed to differences in eGFR distribution among various CKD causes.

Explanations of the relationship between hs‐TnT and LV structural and functional abnormalities remain speculative. LVH is caused by LV pressure and/or volume overload in an attempt to maintain wall stress, which in turn leads to myocyte death that may be further exacerbated by decreased coronary perfusion, and uremia.[21](#jah34438-bib-0021){ref-type="ref"}, [26](#jah34438-bib-0026){ref-type="ref"} In particular, uremia is an important factors for changing myocardial structure regardless of pressure and volume overload in both animal and human studies.[27](#jah34438-bib-0027){ref-type="ref"}, [28](#jah34438-bib-0028){ref-type="ref"} Renal impairment provokes accumulation of hypertrophic substances related to uremia such as EDN1 (endothelin 1), parathyroid hormone, TNF‐α (tumor necrosis factor α), and IL‐1α (interleukin 1α) and IL‐6.[29](#jah34438-bib-0029){ref-type="ref"} In addition, LVH may lead to release of hs‐TnT in hypertrophied hearts, possibly reflecting changes in cell membrane permeability and myocardial protein turnover.[20](#jah34438-bib-0020){ref-type="ref"}, [30](#jah34438-bib-0030){ref-type="ref"}

Systolic and diastolic dysfunction is associated with increased hs‐TnT in the both general population[4](#jah34438-bib-0004){ref-type="ref"}, [5](#jah34438-bib-0005){ref-type="ref"} and in patients with end‐stage renal disease.[31](#jah34438-bib-0031){ref-type="ref"}, [32](#jah34438-bib-0032){ref-type="ref"}, [33](#jah34438-bib-0033){ref-type="ref"} Studies on non--dialysis‐dependent CKD patients are rare, thus the results of the present study may help enrich our understanding of the relationship among hs‐TnT, CKD, and cardiovascular disease. Indeed, we observed an independent association between the highest quartile hs‐TnT group and diastolic dysfunction independent of renal function. In contrast to the CRIC (Chronic Renal Insufficiency Cohort) study,[20](#jah34438-bib-0020){ref-type="ref"} an association between hs‐TnT and systolic dysfunction was not identified in our study; however, we did find that hs‐TnT was associated with diastolic dysfunction. At enrollment, participants who were previously diagnosed with congestive heart failure (New York Heart Association functional class III or IV) were excluded in the KNOW‐CKD cohort. Consequently, it was difficult to perform additional analyses for systolic dysfunction.

The results of our study suggest continuous hs‐TnT as a possible screening test for LVH and systolic and diastolic dysfunction, regardless of renal function, before additional costly evaluation such as echocardiographic study. Specifically, statistically significant differences were noted between the areas under the curve according to renal function for all outcomes. We carried out additional analyses to identify optimal values of hs‐TnT and found that the ideal cutoff values for hs‐TnT were higher in patients with a lower eGFR for LVH and systolic and diastolic dysfunction. These findings suggest that hs‐TnT might be affected by renal function. However, because of the low prevalence of LVH and LV systolic or diastolic dysfunction among our study participants, the positive predictive values were very low. Positive and negative likelihood ratios were calculated to reduce the influence of low prevalence (Table [3](#jah34438-tbl-0003){ref-type="table"}), and the results suggested that hs‐TnT alone has some limitation as a definitive screening test for LVH and LV dysfunction. However, considering that echocardiography is an expensive test, the present study showed the possibility of hs‐TnT as a simple and cost‐effective test for risk stratification for patients who need further echocardiographic evaluation.

To elucidate the temporal relationship between hs‐TnT and LV structural and functional abnormalities, we conducted additional analyses using follow‐up data. Follow‐up echocardiography at 4 years was offered to all participants, regardless of cardiac symptoms. Those who died or developed end‐stage renal disease before 4 years or who did not reach 4‐year follow‐up did not undergo repeated echocardiography. Higher hs‐TnT levels were associated only with development of LVH and not with diastolic dysfunction. However, because the number of participants who underwent follow‐up echocardiography was small, further analyses are warranted to elucidate the causal relationships between hs‐TnT and changes in cardiac structure and function over time.

Several limitations of this study deserve attention. First, we depended on a single hs‐TnT measurement and thus were unable to perform additional analyses of changes of hs‐TnT levels over time. Second, this study was conducted exclusively in an Asian population without preexisting severe heart failure. In addition, relatively few patients had systolic dysfunction, and this limited the statistical power. Moreover, echocardiographic interpretations could be prone to poor interrater reliability depending on the settings, and the echocardiography was conducted by different cardiologists. Nonetheless, we shared the same formula for calculating LV mass index and uniform echocardiographic measurement of E/e′ at the medial annulus of the mitral valve. Last, echocardiographic follow‐up was conducted in \<50% of the study participants for various reasons, including dialysis initiation, death, and dropout.

In summary, hs‐TnT was strongly associated with alterations of LV structure and diastolic dysfunction. These tendencies persisted in a stratified analysis according to eGFR. Although the predictive power was limited in the low eGFR group, hs‐TnT measurement from CKD patients appears to be a useful targeted strategy that can be used for risk stratification of patients who may need further cardiac evaluation, regardless of renal function. The results of a 4‐year follow‐up showed that increased cardiac TnT was associated with development of LVH. If such an hs‐TnT screening test were incorporated, patients identified at higher risk should be encouraged to perform further evaluations regularly or to undergo more targeted interventions to reduce their risk of LVH and diastolic dysfunction. Further studies are needed to confirm the ideal cutoff values of hs‐TnT in various CKD populations, and such efforts will help early detection of cardiac structural and functional abnormalities and improve cardiovascular outcomes for patients with CKD.
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**Figure S1.** Distributions of high‐sensitivity TnT (troponin T) in the KNOW‐CKD (Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease) cohort.

**Figure S2.** Receiver operating characteristic curve and area under the curve after adjustment of covariables according to renal function.

**Figure S3.** Elevated high‐sensitivity TnT (troponin T) is associated with development of left ventricular hypertrophy in patients with chronic kidney disease at the fourth year after enrollment.
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